What are the benefits and harms of nabiximols (THC and CBD) for adults with opioid-refractory cancer pain?

Nabiximols (THC and CBD) show no significant benefit over placebo in managing opioid-refractory cancer pain, and no increased risk of serious adverse effects; thus, it should not be a recommended treatment in this context.

Authors

Tripdatabase

Publication Details

Journal: Zenodo (CERN European Organization for Nuclear Research)
Published: 2026-11-06
DOI: https://doi.org/10.5281/zenodo.24001352
Primary Topic: Cannabis and Cannabinoid Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

NOV

article

What are the benefits and harms of nabiximols (THC and CBD) for adults with opioid-refractory cancer pain?

Tripdatabase

Nov 6, 2026

3 links

Zenodo (CERN European Organization for Nuclear Research)

Cannabis and Cannabinoid Research

article

What are the benefits and harms of nabiximols (THC and CBD) for adults with opioid-refractory cancer pain?

Tripdatabase

November 6, 2026article en

Abstract

Zenodo (CERN European Organization for Nuclear Research)

Good health and well-being

Openalex Percentile: Top 18%

Cannabis and Cannabinoid Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon

What are the benefits and harms of nabiximols (THC and CBD) for adults with opioid-refractory cancer pain? — Tripdatabase · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS